Cleo Diagnostics (ASX:COV) is attempting to bring to market a simple blood test for the accurate and early diagnosis of ovarian cancer based on the novel patented CXCL10 biomarker, which is produced early and at high levels by ovarian cancers but is largely absent in nonmalignant disease. The test aims to distinguish benign from malignant growths in a standard format that will be readily compatible with existing equipment used by diagnostic laboratories worldwide | Investor presentation: https://cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research/1.0/file/2924-02774453-3A636747
OVT
0.007
250%
X2M
0.016
-46.7%
OLY
0.115
167.4%
ERA
0.002
-33.3%
GBZ
0.013
116.7%
JAV
0.002
-33.3%
CDE
0.07
105.9%
PRM
0.002
-33.3%
GMN
0.002
100%
ANX
0.005
-28.6%
LOC
0.23
70.4%
PV1
0.014
-26.3%
CLG
0.035
66.7%
ALM
0.003
-25%
MGU
0.005
66.7%
AMS
0.003
-25%
SPQ
0.005
66.7%
GTR
0.003
-25%
IFG
0.016
60%
IRD
0.025
-24.2%
ION
0.041
57.7%
RMI
0.013
-23.5%
SRL
0.99
52.3%
CXU
0.007
-22.2%
AX8
0.009
50%
EE1
0.004
-20%
ECT
0.003
50%
RDN
0.004
-20%
TMK
0.003
50%
SPG
0.29
-19.4%
RPG
0.052
48.6%
RWL
0.15
-18.9%
DXN
0.073
46%
A3D
0.037
-17.8%
BOC
0.54
44%
CST
0.056
-17.6%
MKL
0.02
42.9%
AN1
0.005
-16.7%
OPL
0.027
42.1%
LU7
0.005
-16.7%
